These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The use of the minipill in adolescence].
    Author: Goncalves ID, Peixoto RM, Mendonca M.
    Journal: J Bras Ginecol; 1988; 98(4):173-4. PubMed ID: 12316031.
    Abstract:
    The use of hormonal contraceptives containing only progestogen is generally not recommended for adolescents. However, for some patients there may be certain advantages, e.g., for those who suffer from cardiac diseases, where more efficient contraceptive methods, such as the use of estrogenic hormonal contraceptives or IUDs are contraindicated. In Brazil today, there is 1 mini-pill on the market. It contains 0.35 mg norethindrone and 0.35 mg norethisterone, and is taken orally once a day. Its advantages include decreased dysmenorrhea and less overall blood loss than for those who do not use contraceptives. It is indicated for patients exhibiting collateral reactions to the estrogenic component of combination pills. Its adverse effects include menstrual irregularities that are not well tolerated by the adolescent and possible formation of ovarian cysts due to lack of synchronized secretion of gonadotropins. It is not recommended for patients with an absolute contraindication for combined hormonal contraceptives that contain estrogens, for prediabetic patients, for patients affected by acute mononucleosis, for patients with a history of frontal ectopic pregnancy, and for patients with genital bleeding of unknown etiology. It is concluded that the mini-pill should not be a 1st choice contraceptive for adolescents and should only be used in clearly recommended cases.
    [Abstract] [Full Text] [Related] [New Search]